All
FDA Issues Warning on BioZorb Markers After Recall Due to Patient Complications
Providers advised to halt use, monitor patients, and report any complications with BioZorb devices to the FDA.
Navigating the Evolving Landscape of Endocrine Therapy in Breast Cancer
Erika Hamilton, MD, discusses how to approach treatment after progression on first-line therapy and hormone receptor-positive breast cancer.
Ready-to-Use 3-Month Leuprolide Depot Formulation Nears FDA Approval
A new drug application for a 3-month depot formulation of leuprolide mesylate has been submitted to the FDA.
Tapotoclax Shows Manageable Safety, Limited Efficacy in High-Risk MDS After HMA Therapy
A phase 1 study of tapotoclax in high-risk myelodysplastic syndromes demonstrated the agent was tolerable but showed limited efficacy.
Intravesical Mitomycin Demonstrates Significant Duration of Response in NMIBC
The FDA is currently evaluating the application of intravesical mitomycin for low-grade intermediate-risk non–muscle-invasive bladder cancer.
Evaluating Cilta-Cel’s Efficacy in the CARTITUDE-4 Trial
Binod Dhakal, MD, MS, discusses how the efficacy results observed with ciltacabtagene autoleucel in the CARTITUDE-4 trial compare with other therapies that are used for the treatment of relapsed/refractory multiple myeloma.
Advances in Targeted Therapies for SCLC Care
Ariel Lopez-Chavez, MD, provides an overview of the most promising advancements in targeted therapies for the treatment of small cell lung cancer.
Pembrolizumab Plus Chemotherapy Enhances Outcomes in Early-Stage TNBC
In an interview with Targeted Oncology, Peter Schmid, MD, PhD, discussed the results from the phase 3 KEYNOTE-522 trial.
Incorporating Immunotherapy Into Hodgkin Lymphoma Treatment Strategies
Stephen M. Ansell, MD, PhD, discusses how immunotherapy is being integrated into treatment for patients with advanced stage Hodgkin lymphoma.
FDA Approves Asciminib in Newly Diagnosed Ph+ CML in Chronic Phase
Asciminib has gained accelerated approval from the FDA for the treatment of patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
Exploring the Benefits of Nab-Sirolimus in Advanced PEComa Treatment
In an interview with Targeted Oncology, Jacob Stein, MD, MPH, discussed nab-sirolimus and its impact on patients with advanced PEComa.
Key Findings From the CARTITUDE-4 Trial of Cilta-Cel in Multiple Myeloma
Binod Dhakal, MD, MS, discusses the safety and efficacy findings from the CARTITUDE-4 trial.
Overview of the CARTITUDE-4 Trial: Cilta-Cel in Multiple Myeloma
Binod Dhakal, MD, MS, provides an overview of the CARTITUDE-4 trial, including its methods, design, and inclusion criteria.
Genetic Clues to Early-Onset TNBC in Black Women
Holly Pederson, MD, and Elisha Hughes, MD, discussed the use of a polygenic risk score to identify why Black women incur higher rates of triple-negative breast cancer at younger ages.
FDA Expands Approval for Jylamvo Oral Methotrexate Solution in ALL
The indication for Jylamvo now includes pediatric patients with acute lymphoblastic leukemia.
AI Outperforms Standard HRD Tests for Breast, Ovarian Cancers
DeepHRD predicted homologous recombination deficiency with greater accuracy than FDA-approved standard molecular tests.
Continued Investigation of T-DXd Shows Promise in Breast Cancer
Sarah Sammons, MD, highlights the need for further investigation into trastuzumab deruxtecan in breast cancer treatment.
Investigational FGFR3-Selective Inhibitor Shows Promise in Urothelial Cancer
TYRA-300 showed promising safety and preliminary antitumor activity in FGFR3-altered metastatic urothelial cancer, with a 54.5% partial response rate and 100% disease control in the SURF301 trial.
FDA Fast Tracks HC-7366 in Relapsed/Refractory Acute Myeloid Leukemia
The FDA granted fast track status to HC-7366 for relapsed/refractory AML treatment.
Comparing Emerging Classes of Endocrine Therapies in Breast Cancer
Erika Hamilton, MD, discusses the different classes of endocrine therapies and how they compare to one another.
Lenvatinib/Pembrolizumab/TACE Regimen Improves PFS in Intermediate-Stage HCC
Josep M. Llovet, MD, PhD, discussed the updated data from the LEAP-012 trial in intermediate-stage hepatocellular carcinoma.
Exploring the Perioperative Treatment Setting in Lung Cancer
An expert addressed the emerging role of immune checkpoint inhibitors in the perioperative space based on findings from the CheckMate 816, IMpower010, PEARLS, and ADAURA trials.
The Targeted Pulse: Unpack The Latest FDA Approvals and Updates, Including A New Dosage For HER2 Cancers
This week’s recap highlights several significant FDA developments. We also cover ongoing successes of pembrolizumab with chemotherapy in NSCLC.
Behind the ECOG-ACRIN E1910 Trial: Blinatumomab in B-ALL
Mark R. Litzow, MD, discusses the methods and design used in the ECOG-ACRIN E1910 trial.
Analysis Shows Perioperative Pembrolizumab Efficacy in NSCLC
Neoadjuvant pembrolizumab with chemotherapy led to greater pathologic regression based on percent residual volume tumor vs placebo plus chemotherapy in patients with early-stage non–small cell lung cancer.
BOVen Regimen Appears Effective in High-Risk MCL
Zanubrutinib, obinutuzumab, and venetoclax delivered promising response and survival data for the treatment of patients with mantle cell lymphoma harboring a TP53 mutation.
Liquid Biopsies Enhance PSMA-Directed Therapies in GU Cancers
Jacob E. Berchuck, MD, discusses the potential of liquid biopsies to enhance clinical decision-making regarding PSMA-directed therapies.
Upcoming Endocrine Therapy Developments Excite in Breast Cancer
Erika Hamilton, MD, discusses how novel endocrine therapies improve treatment for metastatic breast cancer.
Emerging Endocrine Therapies in Breast Cancer Treatment
Erika Hamilton, MD, discusses some of the most promising endocrine therapies in breast cancer.
Developing a Malignant Hematology and Bone Marrow Transplant APP Fellowship
Janelle Vicens, DNP, APRN, FNP-BC, and Sandra Sepulveda, AGPNP-BC, MSN, BMTCN, discussed what went into developing this Malignant Hematology and Bone Marrow Transplant APP Fellowship.
